ARLINGTON, VA (May 14, 2012) - Vaccination studies from Mercer University (Ga.) headline the groundbreaking research being unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). The conference takes place Monday, May 21 - Wednesday, May 23 at the Sheraton San Diego Hotel and Marina. Other topics to be discussed include diversity and complexity of vaccine manufacturing, scale-up and tech transfer strategies, applications of multi-scale systems pharmacology, and advances in novel small protein therapeutic modalities.
Development of Microparticulate Vaccine for Enhanced Innate Immune Recognition
Meningitis is a deadly bacterial disease prevalent among children. It has a quick onset of action and high fatality rate. Once infected, it may spread from the brain to other parts of the body within 24-48 hours, causing a rash that can lead to amputation of limbs, hearing or vision loss and sometimes fatality. Vaccines may play an important role in the prevention of this disease as they help to generate immunity against the bacteria before it can cause infection. Research presented offers cost-effective and convenient alternatives to current options.
"Although vaccines are available for meningitis, our research focuses on the development of an oral vaccine that can be needle free and patient compliant," said Martin D'Souza, Ph.D., director of graduate programs and co-director of the Center for Drug Delivery Research at Mercer University. "This vaccine is delivered in the form of spherical bead like particles called microparticles that protect the vaccine's degradation from acid in the stomach and ensure its delivery to the intestine where the microparticles are taken up by specialized M-cells and further presented to the body's immune system."
Currently, this research is focusing on the evaluation of an immune response in an in vitro cell culture model and we will be
|Contact: Kimberly Brown|
American Association of Pharmaceutical Scientists